GlassScriptPhysician profile
Megan Hanson
NPI 1922503515
$10,510.16
in general payments reported to CMS, 2019-2025
29 companies · $839 in 2025
The $839 reported for 2025 was more than what a typical Gastroenterology (Registered Nurse) provider received nationally (typical 2025 total: $239).
See the full distribution for Gastroenterology (Registered Nurse)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,023 · 2022: $2,980 · 2023: $2,726 · 2024: $1,942 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,392 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,391.84 |
| Education | $115.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,912.34 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,724.95 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $1,541.93 | 2021-2024 | Entyvio |
| Janssen Biotech, INC. | $910.44 | 2022-2024 | Stelara, Simponi Aria, Remicade |
| Ardelyx, INC. | $503.08 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $412.31 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $361.46 | 2023-2025 | Dupixent |
| Redhill Biopharma INC. | $300.47 | 2021-2023 | Talicia |
| Pfizer INC. | $292.32 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $272.25 | 2021-2024 | Ocaliva |
| Celgene Corporation | $197.69 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $175.61 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $157.94 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $109.59 | 2023 | |
| Madrigal Pharmaceuticals | $93.49 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $80.31 | 2022-2023 | |
| Celltrion USA INC. | $76.92 | 2025 | Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.53 | 2024 | Cyltezo |
| Axonics, INC. | $49.83 | 2022-2023 | Axonics |
| Novo Nordisk INC | $43.74 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $42.98 | 2021-2022 | |
| Evoke Pharma, INC. | $38.43 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $37.01 | 2025 | Zenpep |
| Amgen INC. | $29.40 | 2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $25.22 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $16.93 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.08 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.12 | 2023 | Rebyota |
| Sumitomo Pharma America, INC. | $14.79 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.